Education
About Us
Working with TipRanks
Follow Us
Esperion (ESPR)
NASDAQ:ESPR
ESPR Stock Chart & Stats
Day’s Range― - ―
52-Week Range$0.69 - $3.94
Previous CloseN/A
Volume1.55M
Average Volume (3M)5.44M
Market Cap
$411.31M
Enterprise Value$706.58M
Total Cash (Recent Filing)$114.63M
Total Debt (Recent Filing)$297.78M
Price to Earnings (P/E)―
Beta2.82
Next Earnings
Nov 05, 2025EPS Estimate
0.02Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.02
Shares Outstanding201,622,820
10 Day Avg. Volume5,306,825
30 Day Avg. Volume5,444,731
Financial Highlights & Ratios
PEG Ratio0.09
Price to Book (P/B)-1.06
Price to Sales (P/S)1.24
P/FCF Ratio-17.18
Enterprise Value/Market Cap1.72
Enterprise Value/Revenue2.72
Enterprise Value/Gross Profit4.17
Enterprise Value/Ebitda-7.99
Forecast
1Y Price Target
$7.13Price Target Upside234.74% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering4
Bulls Say, Bears Say
Bulls Say
EarningsEsperion announced financial results that showed a significantly better EPS than both the company's and consensus estimates, indicating strong financial performance.
Product DevelopmentThe development of two triple combination products underway in the U.S. provides potential for significant life-cycle extension and patent protection.
Strategic PartnershipsEsperion announced a license and distribution agreement with HLS Therapeutics for the commercialization of NEXLETOL and NEXLIZET in Canada.
Bears Say
Market CompetitionEsperion is making strides to position BDA as the drug of choice over statins and PCSK9 inhibitors, which is expected to drive continued accelerated growth for the company’s commercial drug.
Sales Growth Requirements≥10%Q/Q Nexletol/Nexlizet sales growth will likely be required to meet current 2025 Street sales consensus of $170MM to provide confidence in the franchise's growth potential and profitability timelines.
Esperion News
ESPR FAQ
What was Esperion’s price range in the past 12 months?
Esperion lowest stock price was $0.69 and its highest was $3.94 in the past 12 months.
What is Esperion’s market cap?
Esperion’s market cap is $411.31M.
When is Esperion’s upcoming earnings report date?
Esperion’s upcoming earnings report date is Nov 05, 2025 which is in 74 days.
How were Esperion’s earnings last quarter?
Esperion released its earnings results on Aug 11, 2025. The company reported -$0.02 earnings per share for the quarter, beating the consensus estimate of -$0.146 by $0.126.
Is Esperion overvalued?
According to Wall Street analysts Esperion’s price is currently Undervalued.
Does Esperion pay dividends?
Esperion does not currently pay dividends.
What is Esperion’s EPS estimate?
Esperion’s EPS estimate is 0.02.
How many shares outstanding does Esperion have?
Esperion has 201,622,820 shares outstanding.
What happened to Esperion’s price movement after its last earnings report?
Esperion reported an EPS of -$0.02 in its last earnings report, beating expectations of -$0.146. Following the earnings report the stock price went down -1.604%.
Which hedge fund is a major shareholder of Esperion?
Currently, no hedge funds are holding shares in ESPR
Esperion Stock Smart Score
Underperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$7.13 (234.74% Upside)
$7.13 (234.74% Upside)
Blogger Sentiment
Bullish
ESPR Sentiment 100%
Sector Average 71%
Sector Average 71%
Hedge Fund Trend
Decreased
By 558.7K Shares
Last Quarter.
Last Quarter.
Insider Transactions
Sold Shares
Worth $50.7K over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Positive
Last 7 Days ▼ 1.3%
Last 30 Days ▲ 3.6%
Last 30 Days ▲ 3.6%
News Sentiment
Neutral
Bullish news 50%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Positive
20 days / 200 days
Momentum
21.02%
12-Months-Change
Fundamentals
Return on Equity
23.44%
Trailing 12-Months
Asset Growth
-1.49%
Trailing 12-Months
Company Description
Esperion
Esperion Therapeutics, Inc., a pharmaceutical company, develops and commercializes medicines for the treatment of patients with elevated low density lipoprotein cholesterol. Its lead product candidates are NEXLETOL (bempedoic acid) and NEXLIZET (bempedoic acid and ezetimibe) tablets for the treatment of patients with atherosclerotic cardiovascular disease or heterozygous familial hypercholesterolemia. The company has a license and collaboration agreement with Daiichi Sankyo Europe GmbH; and Serometrix to in-license its oral, small molecule PCSK9 inhibitor program. Esperion Therapeutics, Inc. was incorporated in 2008 and is headquartered in Ann Arbor, Michigan.
ESPR Company Deck
ESPR Earnings Call
Q2 2025
0:00 / 0:00
Earnings Call Sentiment|Positive
The earnings call highlighted Esperion's robust financial performance with significant revenue growth and strategic achievements, such as achieving operating income for the first time and strong international partnerships. While there were some concerns about collaboration revenue and milestone payments, the positive aspects of the company's growth and strategic initiatives significantly outweigh the challenges.View all ESPR earnings summariesESPR Stock 12 Month Forecast
Average Price Target
$7.13
▲(234.74% Upside)
Technical Analysis
Emergent Biosolutions
―
Ironwood Pharma
―
Lifecore Biomedical
―
Aquestive Therapeutics
―
Journey Medical Corp
―
Ownership Overview
1.57% Insiders
13.69% Mutual Funds
17.13% Other Institutional Investors
58.60% Public Companies and
Individual Investors